Jul 27, 2021

Starpharma (ASX:SPL) shows 99.99pc antiviral activity against Delta COVID-19 variant

Starpharma (ASX:SPL) shows 99.99pc antiviral activity against Delta COVID-19 variant

"Starpharma's (SPL) SPL7013 drug has shown a reduction of more than 99.99 per cent against the Delta variant of SARS-CoV-2," The Market Herald reports. Read the full article here

 This contains certain forward-looking statements.